Skip to main content

Table 3 Accuracy data

From: Stability-indicating method development and validation for the concurrent determination of darunavir, cobicistat, emtricitabine and tenofovir alafenamide by UPLC in bulk and tablet dosage forms

Level in %

Sample conc. (µg)

Std conc. (µg)

Amount Std recovered

% Recovery

%Mean recovery

TAF

50%

5

2.5

2.49

99.62

99.87

100%

5

5

4.99

99.70

 

150%

5

7.5

7.52

100.30

 

COBI

50%

75

37.5

37.17

99.12

100.05

100%

75

75

75.71

100.95

 

150%

75

112.5

112.59

100.1

 

FTC

50%

100

50

49.99

99.98

99.53

100%

100

100

99.31

99.31

 

150%

100

150

148.93

99.30

 

DRV

50%

400

200

199.97

99.99

99.67

100%

400

400

399.69

99.92

 

150%

400

600

594.37

99.10

 
  1. Values are average of triplicate samples
  2. TAF tenofovir alafenamide, COBI cobicistat, FTC emtricitabine, DRV darunavir, μg/mL microgram/millilitre, % percentage, μg microgram